Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA NephropathyPRNewsWire • 10/19/22
Calliditas' partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathyPRNewsWire • 09/20/22
Can Calliditas Therapeutics AB Sponsored ADR (CALT) Climb 160% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/15/22
How Much Upside is Left in Calliditas Therapeutics AB Sponsored ADR (CALT)? Wall Street Analysts Think 200%Zacks Investment Research • 07/28/22
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas TherapeuticsPRNewsWire • 07/18/22
Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2018/2022PRNewsWire • 03/24/22
Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South KoreaPRNewsWire • 03/14/22
Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™PRNewsWire • 01/28/22